July 26, 2017 / 8:59 PM / 2 years ago

BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

July 26 (Reuters) - Emergent Biosolutions Inc

* Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva’s zika vaccine technology, ZIKV​

* Emergent biosolutions inc - ‍emergent and valneva will co-develop zikv-vla1601​

* Emergent Biosolutions Inc - ‍under terms of agreement, emergent will pay Valneva eur 1 million upfront​

* Emergent Biosolutions Inc - ‍companies plan to initiate phase 1 trial in late 2017 or early 2018​

* Emergent Biosolutions - cos will share all costs until availability of phase 1 data, which is anticipated within six months from trial initiation​

* Emergent - ‍will have option to continue development arrangement with valneva for a milestone payment of eur 5 million, upon availability of phase 1 data​

* Emergent Biosolutions Inc - ‍agreement also provides valneva potential additional milestone payments of up to eur 44 million​

* Emergent Biosolutions Inc - ‍companies are expected to enter into a technology transfer agreement at a later time​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below